Syngene Intl.

  • Market Cap: Small Cap
  • Industry: Healthcare Services
  • ISIN: INE398R01022
  • NSEID: SYNGENE
  • BSEID: 539268
INR
637.80
-4.6 (-0.72%)
BSENSE

Dec 05

BSE+NSE Vol: 1.59 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Syngene International Ltd stock-summary
stock-summary
Syngene International Ltd
Small Cap
Healthcare Services
Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Headquartered in India, the operations are driven by its highly qualified teams comprising ~6000 scientists and its state-of-the-art facilities, spread over 2.2 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
Company Coordinates stock-summary
Company Details
Biocon SEZ Biocon Park, Plot No 2 & 3 Bommasandra Inds Bengaluru Karnataka : 560099
stock-summary
Tel: 91-80-68915000/67758781
stock-summary
investor@syngeneintl.com
Registrar Details
Karvy Computershare Pvt Ltd., Karvy Selenium, Tower-B Plot No 31 & 32, Survey No 116/22, 115/24, 115/25, Financial District, Nanakramguda, Serilingampally, Mandal Ranga Reddy Dist, Hyderabad
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR 402.54 Cr
Number of Shares
40.25 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
24-Apr-2024
40.25
402.54
521981
10
Issued under ESOP Scheme
26-Apr-2023
40.2
402.01
580500
10
Issued under ESOP Scheme
27-Apr-2022
40.14
401.43
638000
10
Issued under ESOP Scheme
27-Apr-2021
40.08
400.80
796500
10
Issued under ESOP Scheme
11-Jun-2019
4
400.00
200000000
10
Bonus
11-Aug-2015
2
200.00
22000000
10
Public Issues
11-Aug-2015
2
200.00
22000000
10
Public Issues
10-Aug-2015
17.8
178.00
-22000000
10
Offer For Sale
10-Aug-2015
17.8
178.00
-22000000
10
Offer For Sale
27-Mar-2015
2
200.00
171931136
10
Bonus
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 32 Schemes (21.22%)

FIIs

Held by 239 FIIs (16.31%)

Promoter with highest holding

Biocon Limited (52.41%)

Highest Public shareholder

Icici Prudential Elss Tax Saver Fund (4.82%)

Individual Investors Holdings

5.28%

stock-summary Board of Directorsstock-summary
stock-summary
Management
Designation
Remuneration
Kiran Mazumdar Shaw
Chairperson
82.3 lacs
Catherine Patricia Rosenberg
Director
72.5 lacs
Paul Frederick Blackburn
Independent Director
79.1 lacs
Vijay Kuchroo
Independent Director
72.5 lacs
Jonathan Hunt
Managing Director & CEO
8.47 cr
Vinita Bali
Lead Independent Director
75.8 lacs
Priyadarshnini Mahapatra
Company Sec. & Compli. Officer
0
Sharmila Karve
Independent Director
75.8 lacs
Carl Decicco
Director
53.0 lacs
Kush Parmar
Independent Director
56.1 lacs
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
Chemicals and Reagents
868.3
0%
 
100
Chemicals and Reagents
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Contract Research and Manufacturing Services Income
1,715.60
93.97%
Export Incentives
54.80
3.00%
Other Operating Income
52.40
2.87%
 
93.97
Contract Research and Manufacturing Services Income
6.03
Contract Research and Manufacturing Services Income
3
Export Incentives
97
Export Incentives
2.87
Other Operating Income
97.13
Other Operating Income
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
911 Cr
(Quarterly Results - Sep 2025)
Net Profit:
67 Cr
stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 25,571 Cr (Small Cap)

stock-summary
P/E

55.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.19%

stock-summary
Debt Equity

-0.11

stock-summary
Return on Equity

9.89%

stock-summary
Price to Book

5.47